Excellence in Dermatology™
Excellence in Dermatologic Surgery™
Excellence in Medical Dermatology™
Excellence in Dermatopathology™

S029 - Cutaneous Oncology

Saturday, February 17; 1:00 PM - 4:00 PM

Learning Objectives

Following this course, the attendee should be able to:

  • Apply strategies in the management of cutaneous squamous cell carcinoma, cutaneous T-cell lymphoma, and rare skin cancers.
  • Discuss dermatopathology tools for prognostication, non-invasive devices, and imaging studies in the management of skin cancers.
  • Describe baseline and surveillance strategies in the current management of melanoma.

Description

This session is directed towards general and surgical dermatologists. Baseline and surveillance strategies in the current management of melanoma will be discussed. It will address advances in the treatment of cutaneous squamous cell carcinoma, cutaneous T-cell lymphoma, and rare skin cancers. The session will also describe the use of dermatopathology prognostication tools, non-invasive devices, and radiology imaging in the management of skin cancers.

Disclosures

  • DeClerck, Brittney Kaufman, MD: no financial relationships exist with commercial interests.
  • Hanlon, Allison, MD, PhD: Merck & Co., Inc – C(Fees);
  • Lee, Patrick K., MD: no financial relationships exist with commercial interests.
  • Markowitz, Orit, MD: 3Gen, LLC – SP(H); Amgen – I(Grants/Research Funding); Caliber Imaging and Diagnostics Inc. – I(EQ); DUSA Pharmaceuticals, Inc – I(OB); Elsevier Inc. – Speaker/Faculty Education(H); Galderma Laboratories, L.P. – I(OB); Leo Pharma Inc – C(H), I(Grants/Research Funding); Lippincott Williams & Wilkins – O(Fees); Lucid, Inc. – I(EQ); MDSolarSciences Corporation – A(NC); MelaSciences – Speaker/Faculty Education(H); Michelson Diagnostics Ltd. – I(EQ); Novartis – I(Grants/Research Funding); Regeneron – C(H); Valeant Pharmaceuticals North America LLC – I(Grants/Research Funding);
  • Querfeld, Christiane, MD, PhD: Actelion – A(H); Celgene Corporation – A(H); Mallinckrodt Pharmaceuticals – A(H); miRagen Therapeutics, Inc. – B(H);
  • Soriano, Teresa Tabora, MD: no financial relationships exist with commercial interests.
  • Wysong, Ashley, MD, MS: Castle Biosciences – I(Grants/Research Funding);
  • Zelac, Daniel Ethan, MD: no financial relationships exist with commercial interests.
Schedule
Saturday, February 17
1:05 PM
Dr. Zelac / Strategies in the current management of melanoma
1:30 PM
Dr. Wysong / Radiographic imaging and surveillance for high risk skin cancers
1:55 PM
Dr. Querfeld / Novel Immune Therapies in Cutaneous T-Cell Lymphoma
2:20 PM
Dr. DeClerck / Pathology & Prognosis: Update on tools for prognostication in cutaneous malignancies
2:45 PM
Dr. Hanlon / Practical guide to unusual skin tumors
3:10 PM
Dr. Markowitz / Non-invasive devices in the management of skin cancers
3:35 PM
Dr. Lee / Current concepts and advances in the management of cutaneous squamous cell carcinoma
Event Details
  • Date
    Saturday, February 17
  • Time
    1:00 PM - 4:00 PM
  • Location
    Room 1B
  • CME Credits
    3.00
  • Type
Directors/Co-Directors
  • Teresa Tabora Soriano, MD, FAAD
Speakers
  • Allison Hanlon, MD, PhD, FAAD
  • Ashley Wysong, MD, MS, FAAD
  • Brittney Kaufman DeClerck, MD, FAAD
  • Christiane Querfeld, MD, PhD, FAAD
  • Daniel Ethan Zelac, MD, FAAD
  • Orit Markowitz, MD, FAAD
  • Patrick K. Lee, MD, FAAD